OVID — Ovid Therapeutics Share Price
0.000.00%
Last trade - 00:00- $228.39m
- $122.56m
- $0.39m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.6 | ||
| Price to Tang. Book | 2.61 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 583.08 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -44.72% | ||
| Return on Equity | -47.57% | ||
| Operating Margin | -15134.4% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 12.62 | 208.38 | 1.5 | 0.39 | 0.24 | 47.5 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.
Directors
- Jeremy Levin CHM (68)
- Jeffrey Rona CFO (53)
- Thomas Perone CCO (56)
- Jason Tardio OTH (44)
- Bart Friedman LED (75)
- Kevin Fitzgerald DRC
- Robert Poole DRC
- Karen Bernstein IND (67)
- Barbara Duncan IND (56)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 1st, 2014
- Public Since
- May 5th, 2017
- No. of Shareholders
- 14
- No. of Employees
- 40
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 70,709,857
- Address
- 441 NINTH AVENUE, 14TH FLOOR, NEW YORK, 10001
- Web
- https://ovidrx.com/
- Phone
- +1 2127764381
- Auditors
- KPMG LLP
Upcoming Events for OVID
Ovid Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Ovid Therapeutics Inc Earnings Release
Similar to OVID
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Ovid Therapeutics share price?
As of Today at 19:16 UTC, shares in Ovid Therapeutics are trading at $3.23. This share price information is delayed by 15 minutes.
How has the Ovid Therapeutics share price performed this year?
Shares in Ovid Therapeutics last closed at $3.23 and the price had moved by +5.9% over the past 365 days. In terms of relative price strength the Ovid Therapeutics share price has underperformed the S&P500 Index by -11.87% over the past year.
What are the analyst and broker recommendations for Ovid Therapeutics?
The overall consensus recommendation for Ovid Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Ovid Therapeutics dividend yield?
Ovid Therapeutics does not currently pay a dividend.
Does Ovid Therapeutics pay a dividend?
Ovid Therapeutics does not currently pay a dividend.
When does Ovid Therapeutics next pay dividends?
Ovid Therapeutics does not currently pay a dividend.
How do I buy Ovid Therapeutics shares?
To buy shares in Ovid Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ovid Therapeutics?
As of the previous close price of $3.23, shares in Ovid Therapeutics had a market capitalisation of $228.39m.
Where are Ovid Therapeutics shares listed?
Here are the trading details for Ovid Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: OVID
What kind of share is Ovid Therapeutics?
Based on an overall assessment of its quality, value and momentum Ovid Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ovid Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Ovid Therapeutics is $7.33. That is 126.93% above the last closing price of $3.23.
Analysts covering Ovid Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.84 for the next financial year.
What is the trend in the Ovid Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ovid Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -20.97%.
As of the last closing price of $3.23, shares in Ovid Therapeutics were trading -5.91% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ovid Therapeutics PE Ratio?
The Ovid Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ovid Therapeutics?
Ovid Therapeutics' management team is headed by:
- Jeremy Levin - CHM
- Jeffrey Rona - CFO
- Thomas Perone - CCO
- Jason Tardio - OTH
- Bart Friedman - LED
- Kevin Fitzgerald - DRC
- Robert Poole - DRC
- Karen Bernstein - IND
- Barbara Duncan - IND